Galapagos NV (GLPG)
25.92
0.10 (0.39%)
At close: Mar 24, 2025, 3:59 PM
25.95
0.12%
After-hours: Mar 24, 2025, 04:41 PM EDT
0.39% (1D)
| Bid | 25.44 |
| Market Cap | 1.71B |
| Revenue (ttm) | -8.97M |
| Net Income (ttm) | 206.33M |
| EPS (ttm) | -0.02 |
| PE Ratio (ttm) | -1296 |
| Forward PE | -36.28 |
| Analyst | Sell |
| Ask | 27.5 |
| Volume | 78,670 |
| Avg. Volume (20D) | 264,063 |
| Open | 25.88 |
| Previous Close | 25.82 |
| Day's Range | 25.86 - 26.08 |
| 52-Week Range | 22.36 - 33.00 |
| Beta | -0.01 |
About GLPG
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The compan...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 27, 2012
Employees 1,123
Stock Exchange NASDAQ
Ticker Symbol GLPG
Website https://www.glpg.com
Analyst Forecast
According to 5 analyst ratings, the average rating for GLPG stock is "Sell." The 12-month stock price forecast is $27, which is an increase of 4.17% from the latest price.
Stock ForecastsNext Earnings Release
Galapagos NV is scheduled to release its earnings on Apr 23, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+2.08%
Galapagos shares are trading lower after the compa...
Unlock content with
Pro Subscription
7 months ago
+9.66%
Galapagos shares are trading higher after Ecor1 Capital reported a 9.9% stake in the company.
